Results 21 to 30 of about 180 (117)

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis [PDF]

CNS Drugs, 2020
During the creation of the HTML version of the article, incorrect body text (including all tables and figures) and an incorrect Additional Information section were uploaded; the PDF version was correct. The HTML version has now been corrected.
Victoria J. Muir, Greg L. Plosker
openaire   +1 more source

Treatment of Multiple Sclerosis with Cladribine Tablets: Literature Review and the Guidance of the Lithuanian Association of Neurologists

Neurologijos seminarai
Cladribine is a disease-modifying drug used for the treatment of the highly active relapsing-remitting form of multiple sclerosis. Cladribine is a purine nucleoside analogue which selectively targets lymphocyte subpopulations involved in the ...
R. Kizlaitienė, D. Mickevičienė, L. Malcienė, N. Giedraitienė, R. Balnytė, D. Jatužis   +5 more
doaj   +3 more sources

Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)

Therapeutic Advances in Neurological Disorders, 2020
Background: The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. Methods: Real-world data (RWD) from Italian MS patients who
Francesco Patti, Andrea Visconti, Antonio Capacchione, Sanjeev Roy, Maria Trojano,   +5 more
doaj   +1 more source

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

Неврология, нейропсихиатрия, психосоматика, 2020
The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS ...
N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika   +14 more
doaj   +1 more source

Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS)

Journal of Central Nervous System Disease, 2022
Background Recently, the number of available disease modifying therapies for multiple sclerosis (MS) has increased. However, a proportion of patients treated with these agents continue to experience relapses and disease progression.
Georgios Tsivgoulis, Spyros Deftereos, Claudio Gobbi, Elisabeth Gulowsen Celius, Alina Kulakowska, Giorgia Maniscalco, Irene Mendes, Nicolaos Grigoriadis   +7 more
doaj   +1 more source

Cladribine tablets and multiple sclerosis: NICE technology appraisal [PDF]

Progress in Neurology and Psychiatry, 2018
Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.1 An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will ...
Tarek Gaber, Clare Shippen
openaire   +1 more source

Prolonged observation after the use of cladribine in multiple sclerosis: efficacy and safety

Неврология, нейропсихиатрия, психосоматика, 2023
Multiple sclerosis (MS) is a chronic disease whose pathogenesis is based on autoimmune neuroinflammatory and neurodegenerative components. The goal of therapy of MS is to reduce the risk of exacerbations and progression of the disease.
A. D. Kukushkina, A. N. Boyko
doaj   +1 more source

Correction to: Cladribine Tablets: A Review in Relapsing MS [PDF]

CNS Drugs, 2019
The article Cladribine Tablets: A Review in Relapsing MS, written by Emma D. Deeks, was originally published Online First without open access.
openaire   +1 more source

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017
Background Multiple sclerosis (MS) diagnostic criteria have changed since the ORACLE-MS study was conducted; 223 of 616 patients (36.2%) would have met the diagnosis of MS vs clinically isolated syndrome (CIS) using the newer criteria.
Mark S Freedman, Thomas P Leist, Giancarlo Comi, Bruce AC Cree, Patricia K Coyle, Hans-Peter Hartung, Patrick Vermersch, Doris Damian, Fernando Dangond   +8 more
doaj   +1 more source

Cladribine tablets added to IFN-β in active relapsing MS [PDF]

Neurology Neuroimmunology & Neuroinflammation, 2018
To evaluate the safety and efficacy of cladribine tablets in patients still experiencing active relapsing MS despite interferon (IFN)-β treatment.A 96-week phase II study, randomizing patients treated with IFN-β to cladribine tablets 3.5 mg/kg/IFN-β or placebo/IFN-β.
Xavier Montalban, Thomas P. Leist, Bruce A. Cohen, Harold Moses, Jackie Campbell, Christine Hicking, Fernando Dangond, Giancarlo Comi, Paolo Gallo, Carlo Pozzilli, Claudio Gasperini, Vincenzo Brescia Morra, Alexey N Boyko, Olga Amelina, Sergey V Kotov, Lilia Novikova, Olga Patrusheva, Igor Zavalishin, Farid Khabirov, Natalia Maslova, Nadezda Malkova, Irina E Poverennova, Xavier Montalban, Sergio Martinez Yelamos, Guillermo Izquierdo, Oscar Fernandez, Alfredo Rodriguez-Antiguedad, Angel Perez Sempere, Rafael Arroyo, Bonaventura Casanova, Manual Arias, Mark Cascione, Bruce Arnold Cohen, Edward Fox, Regina Berkovich, Michael Kaufman, Thomas Leist, Dina Jacobs, Tamara Miller, Harold Moses, Michael Racke, George Hutton, Barry Singer, Kiren Kresa-Reahl, Emily Pharr, Jonathan L Carter, Jeanette Wendt, Rup Tandan, Roberto Bomprezzi, Corey Ford, Stephen Kamin, Misha Pless, George P Garmany, Suzanne Gazda, Jeffrey English, Barbara Green, Dennis Garwacki, Jeffrey Gould, Chris LaGanke   +58 more
openaire   +2 more sources